No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Ahmet Yalcinkaya; Marco Cavalli; Axel Cederholm; Maribel Aranda-Guillén; Anish Behere; Hedvig Mildner; Tadepally Lakshmikanth; Laura Gonzalez; Constantin Habimana Mugabo; Anette Johnsson; Olov Ekwall; Olle Kämpe; Sophie Bensing; Petter Brodin; Pär Hallberg; Mia Wadelius; Nils Landegren

doi:10.1038/s41541-024-00829-9

npj Vaccines (Feb 2024)

No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Ahmet Yalcinkaya,
Marco Cavalli,
Axel Cederholm,
Maribel Aranda-Guillén,
Anish Behere,
Hedvig Mildner,
Tadepally Lakshmikanth,
Laura Gonzalez,
Constantin Habimana Mugabo,
Anette Johnsson,
Olov Ekwall,
Olle Kämpe,
Sophie Bensing,
Petter Brodin,
Pär Hallberg,
Mia Wadelius,
Nils Landegren

Affiliations

Ahmet Yalcinkaya: Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University
Marco Cavalli: Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University
Axel Cederholm: Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University
Maribel Aranda-Guillén: Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet
Anish Behere: Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University
Hedvig Mildner: Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University
Tadepally Lakshmikanth: Department of Women’s and Children’s Health, Karolinska Institutet
Laura Gonzalez: Department of Women’s and Children’s Health, Karolinska Institutet
Constantin Habimana Mugabo: Department of Women’s and Children’s Health, Karolinska Institutet
Anette Johnsson: Department of Women’s and Children’s Health, Karolinska Institutet
Olov Ekwall: Department of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg
Olle Kämpe: Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet
Sophie Bensing: Department of Endocrinology, Karolinska University Hospital
Petter Brodin: Department of Women’s and Children’s Health, Karolinska Institutet
Pär Hallberg: Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University
Mia Wadelius: Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University
Nils Landegren: Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University

DOI: https://doi.org/10.1038/s41541-024-00829-9
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.

Published in npj Vaccines

ISSN: 2059-0105 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.nature.com/npjvaccines/

About the journal